SEARCH

SEARCH BY CITATION

References

  • Armitage, J.O., Vose, J.M. & Weisenburger, D.D. (2004) Towards understanding the peripheral T-cell lymphomas. Annals of Oncology, 15, 14471449.
  • Armitage, J., Vose, J. & Weisenburger, D. (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. Journal of Clinical Oncology, 26, 41244130. Epub 2008 Jul 4114.
  • Blystad, A.K., Enblad, G., Kvaloy, S., Berglund, A., Delabie, J., Holte, H., Carlson, K., Kvalheim, G., Bengtsson, M. & Hagberg, H. (2001) High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplantation, 27, 711716.
  • Chan, W.C., Armitage, J.O., Gascoyne, R.D., Connors, J., Close, P., Jacobs, P., Norton, A., Lister, T.A., Pedrinis, E., Cavalli, F., Berger, F., Coiffier, B., Ho, F., Liang, R., Ott, G., Hiddemann, W., Diebold, J., MacLennan, K.A., Muller-Hermelink, H.K., Nathwani, B.N., Weisenburger, D.D. & Harris, N.L. (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma classification project. Blood, 89, 39093918.
  • Chen, A.I., McMillan, A., Negrin, R.S., Horning, S.J. & Laport, G.G. (2008) Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the stanford experience. Biol Blood Marrow Transplant, 14, 741747.
  • Corradini, P., Dodero, A., Zallio, F., Caracciolo, D., Casini, M., Bregni, M., Narni, F., Patriarca, F., Boccadoro, M., Benedetti, F., Rambaldi, A., Gianni, A.M. & Tarella, C. (2004) Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. Journal of Clinical Oncology, 22, 21722176.
  • Corradini, P., Tarella, C., Zallio, F., Dodero, A., Zanni, M., Valagussa, P., Gianni, A.M., Rambaldi, A., Barbui, T. & Cortelazzo, S. (2006) Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia, 20, 15331538. Epub 2006 Jul 1527.
  • D’amore, F., Relander, T., Lauritzser, G., Jantunen, E., Hagberg, H., Anderson, H., Cavallin-Stahl, E., Holte, H., Osterborg, A., Merup, M., Hansen, M., Telhaug, R., Erlanson, M., Kuittinen, O., Delabie, J., Sundström, C., Ralfkiaer, E., Vornanen, M. & Jensen, C. (2006) Dose-Dence induction followed by autologous stem cell transplant (ASCT) as first-line treatment in peripheral T cell lymphomas (PTCL) – A phase II study of Nordic lymphoma group (NLG). Blood, 108, American Society of Hematology Meeting Abstract, 401.
  • Gallamini, A., Zaja, F., Patti, C., Billio, A., Specchia, M.R., Tucci, A., Levis, A., Manna, A., Secondo, V., Rigacci, L., Pinto, A., Iannitto, E., Zoli, V., Torchio, P., Pileri, S. & Tarella, C. (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood, 110, 23162323. Epub 2007 Jun 2320.
  • Gascoyne, R.D., Aoun, P., Wu, D., Chhanabhai, M., Skinnider, B.F., Greiner, T.C., Morris, S.W., Connors, J.M., Vose, J.M., Viswanatha, D.S., Coldman, A. & Weisenburger, D.D. (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood, 93, 39133921.
  • Gisselbrecht, C., Gaulard, P., Lepage, E., Coiffier, B., Briere, J., Haioun, C., Cazals-Hatem, D., Bosly, A., Xerri, L., Tilly, H., Berger, F., Bouhabdallah, R. & Diebold, J. (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood, 92, 7682.
  • Gressin, R., Garban, F., Peoc’h, M., Jacob, M., Pegourie Bandelier, B., Molina, L., Swiercz, P. & Sotto, J. (2000) Confirmation a long terme.de l’efficacite du schema VIP/ABVD dans le traitement des lymphomes T périphériques non anaplasiques et anaplasiques. Hematologie, 6, 104, Abstract, 1180.
  • Haim, N., Rosenblatt, E., Wollner, M., Ben-Shahar, M., Epelbaum, R. & Robinson, E. (1992) Salvage therapy for non-Hodgkin’s lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin. Cancer Chemotherapy and Pharmacology, 30, 243244.
  • Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K., Cleary, M.L., Delsol, G., De Wolf-Peeters, C., Falini, B., Gatter, K.C., Grogan, T., Isaacson, P., Knowles, D., Mason, D., Muller-Hermelink, H., Pileri, S., Piris, M., Ralfkiaer, E. & Warncke, R. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 13611392.
  • Horwitz, S.M. (2008) Novel therapies and role of transplant in the treatment of peripheral T-cell lymphomas. Hematology American Society of Hematology Education Program, 2008, 289296.
  • Karakas, T., Bergmann, L., Stutte, H.J., Jager, E., Knuth, A., Weidmann, E., Mitrou, P.S. & Hoelzer, D. (1996) Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Leukaemia & Lymphoma, 24, 121129.
  • Le Gouill, S., Milpied, N., Buzyn, A., De Latour, R.P., Vernant, J.P., Mohty, M., Moles, M.P., Bouabdallah, K., Bulabois, C.E., Dupuis, J., Rio, B., Gratecos, N., Yakoub-Agha, I., Attal, M., Tournilhac, O., Decaudin, D., Bourhis, J.H., Blaise, D., Volteau, C. & Michallet, M. (2008) Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Journal of Clinical Oncology, 26, 22642271. Epub 2008 Apr 2267.
  • Lopez-Guillermo, A., Cid, J., Salar, A., Lopez, A., Montalban, C., Castrillo, J.M., Gonzalez, M., Ribera, J.M., Brunet, S., Garcia-Conde, J., Fernandez de Sevilla, A., Bosch, F. & Montserrat, E. (1998) Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Annals of oncology, 9, 849855.
  • Mercadal, S., Briones, J., Xicoy, B., Pedro, C., Escoda, L., Estany, C., Camos, M., Colomo, L., Espinosa, I., Martinez, S., Ribera, J.M., Martino, R., Gutierrez-Garcia, G., Montserrat, E. & Lopez-Guillermo, A. (2008) Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Annals of Oncology, 19, 958963.
  • Miller, A.B., Hoogstraten, B., Staquet, M. & Winkler, A. (1981) Reporting results of cancer treatment. Cancer, 47, 207214.
  • Nichols, C.R., Loehrer, Sr, P.J., Greist, A., Kubilis, P.S. & Hoffman, R. (1988) Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin. Medical and Pediatric Oncology, 16, 1216.
  • O’Connor, O.A., Hamlin, P.A., Portlock, C., Moskowitz, C.H., Noy, A., Straus, D.J., Macgregor-Cortelli, B., Neylon, E., Sarasohn, D., Dumetrescu, O., Mould, D.R., Fleischer, M., Zelenetz, A.D., Sirotnak, F. & Horwitz, S. (2007) Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. British Journal Haematology, 139, 425428.
  • Piekarz, R.L., Robey, R.W., Zhan, Z., Kayastha, G., Sayah, A., Abdeldaim, A.H., Torrico, S. & Bates, S.E. (2004) T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood, 103, 46364643. Epub 2004 Mar 4632.
  • Reimer, P., Rudiger, T., Geissinger, E., Weissinger, F., Nerl, C., Schmitz, N., Engert, A., Einsele, H., Muller-Hermelink, H.K. & Wilhelm, M. (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. Journal of Clinical Oncology, 27, 106113.
  • Ribrag, V., Nasr, F., Bouhris, J.H., Bosq, J., Brault, P., Girinsky, T., Cosset, J.M., Munck, J.N., Corti, C., Decaudin, D., Pico, J.L., Hayat, M. & Carde, P. (1998) VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin’s disease. Bone Marrow Transplantation, 21, 969974.
  • Rodriguez, J., Conde, E., Gutierrez, A., Arranz, R., Leon, A., Marin, J., Bendandi, M., Albo, C. & Caballero, M.D. (2007) The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Annals of Oncology, 18, 652657.
  • Savage, K.J. (2005) Aggressive peripheral T-cell lymphomas (specified and unspecified types). Hematology American Society of Hematology Education Program, 2005, 267277.
  • Savage, K.J., Chhanabhai, M., Gascoyne, R.D. & Connors, J.M. (2004) Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Annals of Oncology, 15, 14671475.
  • Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S., Stein, H., Thiele, J. & Vardiman, J. (2008) WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. IARC, Lyon.
  • Wohrer, S., Chott, A., Drach, J., Puspok, A., Hejna, M., Hoffmann, M. & Raderer, M. (2004) Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. Annals of Oncology, 15, 16801683.
  • Zinzani, P.L., Martelli, M., Magagnoli, M., Zaccaria, A., Ronconi, F., Cantonetti, M., Bocchia, M., Marra, R., Gobbi, M., Falini, B., Gherlinzoni, F., Moretti, L., De Renzo, A., Mazza, P., Pavone, E., Sabattini, E., Amendola, A., Bendandi, M., Pileri, S.A., Mandelli, F. & Tura, S. (1998) Anaplastic large cell lymphoma Hodgkin’s-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapy. Blood, 92, 790794.